AT278 data published in peer-reviewed journal

Summary by AI BETAClose X

Arecor Therapeutics plc announced the peer-reviewed publication of its AT278-104 study in Diabetes, Obesity & Metabolism, demonstrating that its investigational ultra-concentrated (500U/mL) insulin aspart formulation, AT278, maintains an ultra-rapid pharmacokinetic and pharmacodynamic profile regardless of BMI. This finding supports AT278's potential as the first ultra-rapid U500 insulin option for individuals with insulin-resistant type 2 diabetes requiring high-dose therapy and reinforces its role in enabling next-generation automated insulin delivery technologies. The study showed AT278 exhibited significantly faster insulin absorption and greater glucose-lowering effects within the first hour compared to standard U100 insulin aspart and U500 human regular insulin, while maintaining a favourable safety profile.

Disclaimer*

UK 100

Latest directors dealings